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mune manifestations including rheumatoid-like arthritis.
Aim of the work: This work is aimed to study the impact of concomitant HCV infection on rheu-
matoid arthritis (RA) patients.
Patients and methods: 110 RA patients (mean age 44.6 ± 12.7, disease duration 7.92 ±
6.56 years) were included. HCV infection was diagnosed by HCV-antibody (HCV-Ab) and poly-
merase chain reaction. Disease activity was assessed using the disease activity score 28 (DAS28)
and radiological damage by a modiﬁed Larsen method. Functional disability was assessed by the
Modiﬁed Health Assessment Questionnaire (MHAQ).
Results: HCV-Ab was detected in 20% and viremia in 12.7% of RA patients. HCV-Ab positive
patients were signiﬁcantly older (p< 0.001) and had a longer disease duration (p= 0.02). No dif-
ferences were found between HCV-Ab positive and -negative patients in DAS28 and modiﬁed Lar-
sen’s scores, however, HCV-Ab positive patients had a higher frequency of deformities (p< 0.005)
associated with older age (p< 0.001) and higher MHAQ scores (p= 0.002), independent of age
and disease duration. They also had a higher frequency of hepatomegaly (p< 0.001) and vasculitisl-Gaber Street, of Nasser El
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140 G.A. Mahmoud et al.(p< 0.001). Hepatomegaly was associated with older age (p= 0.004) and longer disease duration
(p= 0.003) while vasculitis was associated with older age (p= 0.02).
Conclusion: Concomitant HCV infection in RA patients is associated with signiﬁcant disability
and comorbidities in the form of hepatomegaly and vasculitis. Hepatomegaly and vasculitis were
associated with older age. Hepatomegaly was also associated with longer disease duration. Screen-
ing for HCV infection is recommended in Egyptian RA patients.
 2011 Egyptian Society for Joint Diseases and Arthritis. Production and hosting by Elsevier B.V.
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Hepatitis C virus (HCV) infection is a global public health prob-
lem affecting 3% of the population worldwide, i.e., about 180
million people [1]. Egypt has the highest prevalence of HCV
infection reaching 14.7% according to the most recent Egyptian
DemographicHealth Survey (EDHS) released in 2009 [2]. Infec-
tionwithHCV causes acute and chronic hepatitis with attending
sequelae of cirrhosis, hepatocellular carcinoma and various
extrahepatic manifestations [3]. Several extrahepatic manifesta-
tions, many of which are autoimmune in nature, have been de-
scribed in association with HCV infection among which,
mixed cryoglobulinemia has the strongest association [4–6].
Additional HCV-related immunologic complications include
autoantibody production, rheumatologic disorders, lichen pla-
nus, immune mediated cytopenias and lymphoproliferative dis-
orders [4]. Among the different clinical disorders associatedwith
HCV infection, articular involvement is a frequent complica-
tion, and the clinical picture of HCV-related arthropathy varies
widely ranging frompolyarthralgia tomonoarticular or oligoar-
ticular intermittent arthritis and symmetric chronic polyarthri-
tis. Monoarticular or oligoarticular involvement affects larger
joints and is typically associated with mixed cryoglobulinemia,
whereas symmetric polyarthritis associated with HCV infection
frequently displays a rheumatoid arthritis (RA) like clinical pic-
ture [7,8]. HCV-related symmetric polyarthritis, in comparison
to RA however, is generally less aggressive, non-nodular, non-
deforming, non-erosive and negative for antibodies against cyc-
lic citrullinated peptides (anti-CCP) [9,10]. It has been suggested
that, in genetically susceptible individuals, HCV can trigger RA
[11,12]. Searching for a causal link between HCV infection and
RA, several authors tested sera from RA patients for HCV-Ab
with conﬂicting results [13–17].
The aim of the present work was to determine the preva-
lence and clinical signiﬁcance of HCV infection among rheu-
matoid arthritis patients.
2. Patients and methods
This study included one hundred and ten RA patients attend-
ing the outpatient clinic of the Rheumatology and Rehabilita-
tion Department, Faculty of Medicine, Cairo University,
between July 2009 and July 2010, and was carried out in accor-
dance with the guidelines of the World Medical Association
(Declaration of Helsinki). All RA patients fulﬁlled the ACR
1987 revised criteria for the classiﬁcation of RA [18].
2.1. Patient assessment
All patients included in this study were subjected to full history
taking and clinical examination. Routine laboratory testsincluded complete blood count (CBC), erythrocyte sedimenta-
tion rate (ESR), serum alanine aminotransferase (ALT), aspar-
tate aminotransferase (AST), albumin, urea, creatinine and
urine analysis. Serum rheumatoid factor (RF) was assayed
with a quantitative immunonephelometry test (Behring,
Marburg, Germany). RF was considered to be positive when
the concentration was higher than the cut-off value of the kit
(15 IU/ml). Antibodies to cyclic citrullinated peptides (anti-
CCP) were measured using the microparticle enzyme immuno-
assay (MEIA) method with the Abbott AxSym (Chicago, IL,
USA). Normal reference level is up to 5 U/ml. Anti-nuclear
antibodies (ANA) were detected by indirect immunoﬂuores-
cence. Abdominal ultrasonography was done for all patients.
Disease activity was determined by the 28 joint count
(DAS28) [19]. A modiﬁed Larsen score was used for assess-
ment of radiological damage in plain radiographs of the hands
and feet [20]. The Modiﬁed Health Assessment Questionnaire
(MHAQ) was used for measuring the functional ability of
the patients [21].
2.2. Diagnosis of HCV infection
All patients were screened for the presence of HCV-Ab in ser-
um using a Microparticle Enzyme Immunoassay (MEIA) test,
with the Abbot AxSYM (Chicago, IL, USA). Patients positive
for HCV-Ab were further tested for the presence of HCV
RNA using a quantitative reverse transcriptase polymerase
chain reaction technique (RT-PCR), (Promega Co., Madison,
WI, USA). The detection limit was 100 IU/ml; weak vire-
mia < 100.000, moderate viremia (>100.000–1000.000
IU/ml), severe viremia > 1000.000 IU/ml.
Statistics: Data were statistically described in terms of
range, mean ± standard deviation (±SD), median, frequen-
cies (number of cases) and percentages when appropriate.
Comparisons were done using Mann Whitney U test, Chi
square (v2) test and exact test where appropriate. A probability
value (p-value) less than 0.05 was considered statistically sig-
niﬁcant. All statistical calculations were done using the com-
puter program SPSS (Statistical Package for the Social
Science; SPSS Inc., Chicago, IL, USA) version 15 for Micro-
soft Windows.
3. Results
3.1. Demographic data of studied patients
This study included 110 patients with RA, 97 patients were
females (88.2%) and 13 were males (11.8%). Their ages ran-
ged from 20 years to 70 years with a mean of 44.6 ±
12.7 years. Their disease duration ranged from 5 months to
34 years with a mean of 7.92 ± 6.56 years. Eighty-seven
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als, 48 low dose oral prednisone, 26 Leﬂunomide and 8
Sulfasalazine.
3.2. Prevalence and risk factors for HCV infection
HCV antibody was detected in 22 of 110 RA patients (20%).
Among the HCV-Ab positive group, ﬁfteen patients were fe-
males and seven were males. Identiﬁed risk factors for HCV
transmission were blood transfusion in 4 patients, surgical
exposure in 8 patients and infected spouse in one patient.
HCV infection was diagnosed in nine patients (40.9%) for
the ﬁrst time in the present study. Thirteen patients (59.1%)
were previously diagnosed to have HCV infection with a dura-
tion ranging from 1.5 to 7 years (mean 3.07 ± 1.70). RA was
diagnosed prior to HCV detection in those patients and they
were investigated for HCV infection because of elevated liver
enzymes. Two patients (9.1%) had received interferon plus
ribavirin combination therapy, but one of them discontinued
antiviral therapy due to ﬂare of RA and the other patient
did not respond to antiviral therapy.
The prevalence of HCV antibody was studied among differ-
ent age groups (from 20 to 40 years, from 40 to 60 years and
>60 years). Patients older than 60 years had the highest prev-
alence of positive HCV-Ab (p= 0.021), Table 1.
Among the 22 HCV-Ab positive patients 14 (63.6%) had
positive viremia as detected by PCR. Viral load was mild in
7, moderate in 5 and severe in 2 patients.
3.3. ALT levels and liver cirrhosis in HCV-Ab positive patients
Persistently elevated liver enzymes were found in 4/22 HCV-Ab
positive patients (18.2%). Among those, 3 patients were positive
for HCV-RNA, i.e. only 3/14 patients with detectable viremia
had elevated ALT levels above the normal reference range.
MeanALT levels were not statistically signiﬁcantly different be-
tween HCV-Ab positive and -negative RA groups (30.41 ±
35.23 versus 19.4 ± 9.79 U/l, respectively, p= 0.12). Liver cir-
rhosis was detected in 4/22 (18.2%) HCV-Ab positive patients
by abdominal ultrasonography. Only one of the 4 cirrhotic cases
had elevated ALT. All 4 cases with liver cirrhosis had detectable
viremia, i.e., 4/14 (28.6%) patients with positive PCR had liver
cirrhosis.Table 1 Prevalence of HCV-Ab in RA patients of different age gro
Age (years) 20–40 (n= 36) 40–6
HCV-Ab positive 2 (5.6%) 16 (2
* p< 0.05.
Table 2 Association of DAS28, MHAQ, anti-CCP titer and RF tit
Undetectable viremia (n= 8) Mild viremia (n= 7)
DAS28 5.21 5.28
MHAQ 1.69 1.25
RF titre 62.4 39.45
Anti-CCP titre 28.7 38.3
Values are expressed as median.3.4. Impact of HCV viremia on disease activity and functional
state in HCV-Ab positive RA patients
DAS28, MHAQ, anti-CCP and RF titers were compared be-
tween HCV-Ab positive patients with undetectable, mild,
moderate or severe levels of viremia; no statistically signiﬁcant
differences were detected (Table 2).
3.5. Comparison between HCV-Ab positive and -negative
patients
3.5.1. Characteristics of arthritis
All patients included in this study had symmetric polyarthritis.
HCV-Ab positive patients were signiﬁcantly older, more fre-
quently male and had a longer disease duration than HCV-
Ab negative patients (p= 0.00, 0.001 and 0.02, respectively).
HCV-Ab positive patients had also signiﬁcantly more frequent
deformities and higher MHAQ scores (p< 0.005 and 0.002,
respectively). The frequency of erosions and modiﬁed Larsen’s
scores, however, were not signiﬁcantly different between both
groups. DAS 28 scores were also not statistically signiﬁcantly
different between both groups (Table 3), HCV-Ab positive pa-
tients, however, had signiﬁcantly higher ESR than HCV-Ab
negative ones (59.18 ± 27.8 versus 44.57 ± 27.2 mm/h,
p= 0.02).
The effect of patient age and disease duration on obtained
results is shown later (Tables 5 and 6).
3.5.2. Autoantibody frequencies
No statistically signiﬁcant differences were found in the fre-
quencies of RF, ANA and anti-CCP between HCV-Ab posi-
tive and -negative patient groups (Table 3).
3.5.3. Extraarticular manifestations in RA patients
There were no statistically signiﬁcant differences between both
groups in the frequency of subcutaneous nodules, ocular man-
ifestations, dry mouth, lymphadenopathy, splenomegaly,
interstitial pulmonary ﬁbrosis (IPF), peripheral neuropathy
or Raynaud’s phenomenon.
HCV-Ab positive RA patients had signiﬁcantly more fre-
quent hepatomegaly (p< 0.001) and vasculitis in the form of
mononeuritis multiplex in 1 patient or palpable purpura in 3
patients (p< 0.001) (Table 4).ups.
0 (n= 63) >60 (n= 11) p-Value
5.4%) 4 (36.4%) 0.021*
er with different levels of HCV viremia.
Moderate viremia (n= 5) Severe viremia (n= 2) p-Value
6.15 6.22 0.76
1.88 1 0.59
73.5 48.5 0.64
33.6 110.9 0.94
Table 3 Clinical and laboratory characteristics of RA patients according to HCV-Ab positivity.
HCV-Ab positive RA group (n= 22) HCV-Ab negative RA group (n= 88) p-Value
Age 26–68 (52.73 ± 10.20) 20–70 (42.57 ± 11.81) <0.001*
Male/Female 7/15 6/82 0.001*
Disease duration (years) 2–34 (11.09 ± 8.30) 0.42–30 (7.13 ± 5.85) 0.02*
Deformities 5 (22.7%) 5 (5.7%) <0.005*
Erosions 17 (77.3%) 63 (71.6%) 0.59
Modiﬁed Larsen score 22–121 (47.36 ± 29.40) 0–110 (36.06 ± 16.73) 0.16
DAS28 3.37–8.03 (5.85 ± 1.47) 1.57–8.25 (5.12 ± 1.71) 0.07
MHAQ score 0.13–2.88 (1.55 ± 0.79) 0–3 (0.94 ± 0.87) 0.002*
RF 17 (77.3%) 61 (69.3%) 0.46
Anti CCP 16 (72.7%) 64 (72.7%) 1
ANA 5 (22.7%) 21 (23.9%) 0.9
Values are expressed as range (mean ± SD), unless otherwise indicated.
* p< 0.05.
Table 4 Frequency of different extraarticular manifestations among HCV-Ab positive and -negative RA patients.
HCV-Ab positive RA group (n= 22) n (%) HCV-Ab negative RA group (n= 88) n (%) p-Value
Subcutaneous nodules 2 (9.1) 19 (21.6) 0.18
Ocular dryness 7 (31.8) 18 (20.5) 0.49
Scleritis 0 (0) 2 (2.3) 0.47
Dry mouth 1 (4.5) 16 (18.2) 0.11
Lymphadenopathy 2 (9.1) 3 (3.4) 0.25
Hepatomegaly 10 (45.5) 10 (11.4) <0.001*
Splenomegaly 2 (9.1) 3 (3.4) 0.25
IPF 4 (18.2) 9 (10.2) 0.30
Peripheral neuropathy 2 (9.1) 4 (4.5) 0.40
Vasculitis 4 (18.2) 0 (0) <0.001*
Raynaud’s phenomenon 0 (0) 4 (4.5) 0.31
* p< 0.05.
Table 5 Characteristics of RA patients according to age group.
20–39 years (n= 36) 40–59 years (n= 63) P 60 years (n= 11) p-Value
DAS28 5.11 ± 1.67 5.34 ± 1.64 5.41 ± 2.13 0.74
MHAQ 0.88 ± 0.84 1.15 ± 0.9 1.11 ± 0.97 0.34
Deformities 0 (0%) 9 (14%) 1 (9%) 0.056
Vasculitis 0 (0%) 2 (3%) 2 (18%) 0.02*
Hepatomegaly 1 (3%) 16 (25%) 3 (27%) 0.004*
Values are expressed as mean ± SD unless otherwise indicated.
* p< 0.05.
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To study the possible confounding effect of age on DAS28,
MHAQ, vasculitis, and hepatomegaly, these parameters were
compared between different age groups. No statistically signif-
icant differences were found in DAS28 and MHAQ with
increasing age. There was a trend towards an increase in the
frequency of deformities with increasing age without reaching
statistical signiﬁcance. The frequencies of vasculitis and hepa-
tomegaly were highest in the age group P 60 years (p= 0.02
and 0.004, respectively (Table 5).
3.7. Effect of disease duration on the clinical picture in RA
patients
To study the contribution of disease duration on the clinical
picture in RA, patients were divided into three groups accord-
ing to disease duration (Table 6). There was a statistically sig-niﬁcant increase in the frequency of deformities, erosive
arthritis and modiﬁed Larsen scores with increasing disease
duration (p< 0.001, p= 0.003 and 0.002, respectively). The
frequency of hepatomegaly was signiﬁcantly associated with
increasing disease duration (p= 0.003). MHAQ scores and
the frequency of vasculitis were not statistically signiﬁcantly
different between patient groups with different disease dura-
tion. It can be concluded that the signiﬁcantly higher MHAQ
score in HCV-Ab positive RA patients (p= 0.002) is indepen-
dently associated with HCV infection irrespective of the age
group and disease duration and is not affected by the level
of viremia (Tables 2, 3, 5 and 6).
4. Discussion
The signiﬁcance of HCV infection in RA patients remains un-
clear. While HCV -Ab were detected with higher frequency
than in the general population in sera of RA patients in studies
Table 6 Characteristics of RA patients according to disease duration.
0–5 years (n= 53) 6–10 years (n= 28) > 10 years (n= 29) p-Value
Deformities 0 (0%) 2 (7%) 8 (28%) <0.001*
Erosive arthritis 33 (62%) 19 (68%) 28 (97%) 0.003*
Modiﬁed Larsen scores 32.39 ± 12.13 34.3 ± 11.3 53 ± 29.9 0.002*
MHAQ 1.01 ± 0.87 0.86 ± 0.77 1.34 ± 1 0.27
Hepatomegaly 4 (8%) 5 (18%) 11 (38%) 0.003*
Vasculitis 0 (0%) 2 (7%) 2 (7%) 0.14
Values are expressed as mean ± SD, unless otherwise indicated.
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this association [15–17,22,23].
Detection of serum anti-HCV antibodies is indicative of
past or active infection. HCV viremia as assessed by RT-
PCR is a much more powerful indicator of chronic hepatitis
due to the virus [24]. In the present study, the prevalence of
HCV-Ab among RA patients was 20%, higher than the re-
ported 14.7% prevalence in Egypt according to the Egyptian
Demographic Health Survey (EDHS) [2], which is in agree-
ment with some authors [13,14]. HCV-RNA was found in
14/22 (63.6%) HCV-Ab positive RA patients as compared to
the 67% prevalence of active viremia in HCV-Ab positive
individuals in the EDHS [2]. Blood transfusion, hospital
admission, exposure to invasive medical procedures e.g. gas-
trointestinal endoscopies and surgeries and repeated injections
are identiﬁed risk factors for HCV transmission in Egypt [25].
RA patients are frequently exposed to these risk factors and
thus may present a high risk group for HCV infection. Besides,
although HCV can cause arthritis fulﬁlling the classiﬁcation
criteria for RA [18] in many patients, generally being non-ero-
sive [7,8], erosions have been reported in 7/23 patients with
chronic hepatitis presenting with symmetric polyarthritis [12].
Therefore, the possibility that some cases with HCV-related
arthritis could have been included among the studied RA pa-
tients cannot be excluded.
In the studied HCV infected RA patients, a higher male/fe-
male ratio and higher frequency of HCV-Ab were found with
increasing age reﬂecting the characteristics of HCV infection in
Egypt [2,25–27]. Guennoc et al. [23] found signiﬁcantly higher
levels of transaminases among HCV-Ab positive RA patients,
however, in the present study, mean ALT levels were not sig-
niﬁcantly different between HCV-Ab positive and -negative
patients.
Approximately 25–30% of patients with chronic HCV
infections have persistently normal ALT levels and are usually
referred to as healthy carriers of HCV [28,29]. In the present
study, the majority of HCV-infected patients had within nor-
mal ALT levels (82% of HCV-Ab positive and 79% of
HCV-RNA positive RA patients), which is in agreement with
Guennoc et al. [23], who found only 2/7 HCV-Ab positive RA
patients to have elevation of serum transaminases above the
normal reference ranges. Therefore, it is recommended to
screen RA patients for HCV infection before initiating immu-
nosuppressive or hepatotoxic drugs.
DAS28, as a measure of disease activity in RA, may in-
crease with age as ESR is one of its components [30]. No sta-
tistically signiﬁcant difference was found in DAS28 between
HCV-Ab positive and -negative RA groups although HCV-
Ab positive patients were signiﬁcantly older (p< 0.001) and
had signiﬁcantly higher ESR (p= 0.02). Furthermore, in thestudied patients, DAS28 was not signiﬁcantly different be-
tween RA patients in different age groups. A possible explana-
tion for the elevated ESR in HCV-Ab positive patients is the
host response to HCV infection [31]. Guennoc et al. [23], how-
ever, found no difference in ESR or C-reactive protein between
HCV-Ab positive and -negative RA patients. Rheumatoid fac-
tor and more recently, anti-CCP titers have been found to cor-
relate with disease activity in RA [32,33]. Along with DAS28,
RF and anti-CCP titers were not statistically signiﬁcantly dif-
ferent between HCV-Ab positive RA patients with undetect-
able, mild, moderate or severe levels of viremia, suggesting
that co-existing HCV infection has no effect on RA disease
activity. MHAQ scores were also not signiﬁcantly different be-
tween HCV-Ab positive patients with different levels of
viremia.
In the studied patients, no statistically signiﬁcant differ-
ences were found in the frequency of erosive arthritis, subcuta-
neous nodules or anti-CCP positivity between HCV-Ab
positive and -negative RA groups, suggesting that the studied
HCV-Ab positive patients had RA with co-existing HCV infec-
tion rather than HCV-related arthritis [7,9,10]. In agreement
with our results, Guennoc et al. [23], did not ﬁnd a signiﬁcant
difference in the frequency of anti-CCP between HCV-Ab po-
sitive and -negative RA patients. RF can be detected in 75–
85% of patients with RA and in 37.5% in patients affected
by HCV presenting with polyarthritis [9]. Antinuclear antibod-
ies (ANA) can be found in 8–54% of HCV infected individuals
[34,35] while in RA, ANA can be present in 20–30% of pa-
tients [36]. In the studied patients, the frequencies of RF and
ANA were not statistically signiﬁcantly different between
HCV-Ab positive and -negative RA patients.
A longer disease duration in RA is associated with more
structural damage and loss of mobility [37]. This was con-
ﬁrmed in the present study where increasing disease duration
was signiﬁcantly associated with higher frequency of deformi-
ties, erosive arthritis and modiﬁed Larsen’s scores (p< 0.001,
p= 0.003, p= 0.002, respectively). HCV-Ab positive patients
had higher, although not statistically signiﬁcant modiﬁed
Larsen’s scores but signiﬁcantly more frequent deformities as
compared to HCV-Ab negative ones (p< 0.005), which may
be explained by the longer disease duration in HCV-Ab posi-
tive patients (p= 0.02).
Disability in RA increases gradually with age and increas-
ing disease duration [38], however, in the present study, no sta-
tistically signiﬁcant differences were found in MHAQ scores in
patient groups with different age and disease duration. Higher
MHAQ scores were found in HCV-Ab positive RA patients,
suggesting that HCV infection is independently associated with
physical disability in RA. In agreement with our results, HCV
seropositive patients, in the absence of advanced liver disease
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part of health related quality of life assessment [39]. In the
present study, however, MHAQ was not signiﬁcantly different
between HCV-Ab positive patients with different levels of
viremia.
Vasculitis is a relatively uncommon extraarticular manifes-
tation of RA affecting less than 5% of RA patients, typically
affecting late middle aged persons with severe RA and long
disease duration [40]. In the present study, there was a higher
incidence of vasculitis in age groups older than 40 years
(p= 0.02) but no association with longer disease duration.
HCV infection may be associated with a systemic vasculitis
with or without mixed cryoglobulinemia [41]. In the HCV-Ab
positive RA group 4/22 HCV-Ab positive patients had vascu-
litis which was signiﬁcantly more frequent than in HCV-Ab
negative patients (p< 0.001). This is in agreement with
Ramos-Casals et al. [42] who found a signiﬁcantly higher fre-
quency of vasculitis among patients with systemic autoimmune
diseases and HCV infection than in those without co-existing
HCV infection. In agreement with Ramos-Casals et al. [42],
no statistically signiﬁcant differences were found in the fre-
quency of sicca features, Raynaud’s phenomenon, lung
involvement, peripheral neuropathy between HCV-Ab positive
and -negative RA groups.
Overt clinical evidence of liver disease in rheumatoid arthri-
tis is considered generally absent, although hepatomegaly has
been reported in 22% of RA patients by scintigraphic scanning
[43]. Hepatic dysfunction in RA is associated with disease
severity and longer disease duration [44]. In this study, a statis-
tically signiﬁcantly higher frequency of hepatomegaly was
found in HCV-Ab positive patients as compared to the
HCV-Ab negative group (p< 0.001), in agreement with
Ramos-Casals et al. [42]. Hepatomegaly was associated with
older age (p= 0.004) and longer disease duration (p= 0.003).
In conclusion, HCV infection is common among Egyptian
RA patients. Most patients with active viremia have normal li-
ver enzymes, indicating the necessity for routine screening of
RA patients for HCV infection in Egypt. Although the pres-
ence of HCV infection has no impact on the disease activity
or severity in RA, it is associated with signiﬁcant disability
as well as comorbidities in the form of hepatomegaly and vas-
culitis which were associated with older age. Hepatomegaly
was also associated with longer disease duration.References
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